雅帆国际旗下私护品牌毓美人凭借“清除高危型HPV病毒”技术受邀出席第33届国际HPV大会(国际乳头瘤病毒大会IPVC)，本届国际HPV大会在西班牙巴塞罗那举行，在全球HPV病毒研究领域最具权威性，毓美人抗HPV的产品技术能被再次邀请参会，无不说明毓美人品牌实力再一次获国际认可！

据毓美人了解到，每一届的国际HPV大会(国际乳头瘤病毒大会IPVC)都汇集了来自世界各地的研究人员、临床医生和其他卫生专业人士，一起分享在全球控制HPV疾病过程中的有关乳头瘤病毒及相关疾病的知识和观点。

而毓美人品牌公司雅帆国际曾委托中国医学病毒最权威科研机构“中国疾病预防控制中心病毒预防控制所”完成了毓美人抗HPV药效学的研究。研究实验结果再一次的证实：毓美人具有“清除高危型HPV病毒、防治宫颈癌”的功效，毓美人产品技术能被国际HPV大会再一次认可，意味着产品技术与国际水平齐肩，是女性私密护理的可靠品牌。

那么在本届国际HPV大会上，HPV研究人员、临床医生和其他卫生专业人士都发表了哪些学术报告呢?毓美人产品技术作为受邀参考者，了解到在大会的第二天下午，大会发表了一条关于《Systematic Analysis of Eight Dna Methylation Markers Demonstrates a Comparable High Diagnostic Performance for Cin3 and Cervical Cancer (ID240)》系统分析表明，8个DNA甲基化标记物对CIN3和宫颈癌具有相当高的诊断价值(ID240)的报告，以下为报告的概要：

Stefanie Dick (Netherlands)

Introduction

By genome-wide DNA methylation profilling we have identified novel methylation markers for the detection of CIN3 and cervical cancer in HPV-positive women. This study systematically evaluates and compares the performance of eight host cell DNA methylation markers for the detection of CIN3 and cervical cancer in cervical scrapes.

Methods

HPV-positive cervical scrapes of controls (n=352) and women diagnosed with CIN3 (n=175) or cervical cancer (n=57) were tested for methylation of host cell genes ASCL1, LHX8, ST6GALNAC5, ZIC1, GHSR, SST, FAM19A4 and miR124-2 using quantitative methylation-specific PCR (qMSP). To evaluate their diagnostic performance, simple logistic regression was performed for single makers and LASSO logistic regression was used to build a marker panel to discriminate between controls and CIN3. Marker performance was visualized by ROC curve, and evaluated by the area under the curve (AUC) and corresponding sensitivity and specificity. Models were verified by leave-one-out cross-validation, and subsequently applied to cervical scrapes of women with cervical cancer.

Results

The methylation levels in cervical scrapes increased significantly with underlying disease severity (all markers p<0.001). AUCs from the single markers were between 0.769 and 0.886. Four markers (ASCL1, LHX8, ZIC,FAM19A4) showed ROC curves with cross-validated AUC>0.80. The single markers detected between 53 and 56 of the 57 cervical cancers. LASSO logistic regression resulted in a bi-marker panel consisting of ASCL1 and LHX8. This panel showed the highest cross-validated AUC (0.881), and detected 80.6% of CIN3 and all cervical cancers at specificity of 84.7%.

Conclusions

All eight methylation markers showed a comparable good performance for triage of HPV- positive women using cervical scrapes. Bi-marker panel ASCL1/LHX8 showed complementarity in the detection of cervical cancer.

These data emphasizes the diagnostic potential of methylation analysis in HPV-based cervical screening.

简介

通过全基因组DNA甲基化分析,我们已经确定了新的甲基化标记物，用于检测HPV阳性妇女的CIN3和宫颈癌。本研究系统地评价和比较了8种宿主细胞DNA甲基化标记在宫颈刮片中检测CIN3和宫颈癌的性能。

方法

用定量甲基化特异性PCR (qMSP) 检测了对照组(n=352) 和诊断为CIN3 (n=175)或宫颈癌(n=57) 的HPV-阳性宫颈刮片里宿主细胞基因ASCL1、LHX8、 ST6GALNAC5、ZIC1、GHSR、 SST、FAM19A4和miR124-2的甲基化。为了评估他们的诊断性能，对单个标记物进行简单的logistic回归分析，并使用LASSO-logistic回归建立一个标记物集台来区分对照组和CIN3。用ROC曲线直观显示标记物性能，用曲线下面积(AUC)和相应的敏感性和特异性来评价。模型通过留一法交叉验证进行核实，随后应用于官颈癌妇女的官颈刮片。

结果

宫颈刮片中甲基化水平随潜在疾病严重程度加重而显著升高(所有指标均p<0.001)。单个标

记物的AUCs在0.769和0.886之间。4个标记物(ASCL1、LHX8、 ZIC、 FAM19A4) 显示ROC曲线，交叉验证AUC>0.80。在57例宫颈癌中，53到56例发现了单一标记物。LASSO-logistic回归分析得出一个由ASCL1和LHX8组成的双标记组合。这个组合显示最高的交叉验证AUC (0.881) ，并检测到80.6%的CIN3和所有宫颈癌的特异性为84.7%。

结论

所有8个甲基化标记物用宫颈刮片对HPV阳性妇女进行分类时显示出相当好的性能。双标记集合ASCL1/LHX8在言颈癌的检测中具有互补性。这些数据强调了甲基化分析在基于HPV的宫颈筛查中的诊断潜力。